Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Weighted Average): 2011-2025

Historic Shares Outstanding (Weighted Average) for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $27.8 million.

  • Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.71% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 1.71%. This contributed to the annual value of $27.4 million for FY2024, which is 2.99% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) is $27.8 million, which was up 0.77% from $27.6 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $27.8 million during Q3 2025, and registered a low of $26.0 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $27.3 million (2024), whereas its average is $27.1 million.
  • Data for Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 30.69% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $26.0 million in 2021, then rose by 0.23% to $26.2 million in 2022, then grew by 1.51% to $26.6 million in 2023, then rose by 2.99% to $27.4 million in 2024, then rose by 1.71% to $27.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $27.8 million for Q3 2025, versus $27.6 million for Q2 2025 and $27.6 million for Q1 2025.